Cancer Prognostics Professors and Supervisors | ApplySharif

Find Academic Supervisors

Find and connect with academic supervisors, professors, and scholars for your research journey.

Showing 721-735 of 4,300 supervisors

Profile data may be stale. It is sourced from public faculty pages.

Gabriella D'OraziView profile

Associate Professor

UniCamillus UniversityItaly

Gabriella D'Orazi is an Associate Professor at UniCamillus University of Rome, specializing in General Pathology. She holds a PhD in Experimental Medicine (1992) from the University of Rome La Sapienza and a Master's in Dietetics and Human Nutrition (2003). Her career includes roles as a University Researcher (1992–2017) and Associate Professor (2017–2024) at the University ‘G. D’Annunzio’ of Chieti, alongside visiting appointments at the National Cancer Institute (NCI, NIH, Bethesda) and the National Cancer Institute ‘Regina Elena’ in Rome. Her research focuses on Molecular Oncology, particularly the regulatory mechanisms of tumor suppressor p53 and HIPK2 in cancer progression and therapy response. She has authored over 137 peer-reviewed publications (H-index: 47), is a member of editorial boards for international journals, and is recognized as a Top Italian Scientist in Biomedical Sciences (2024). Teaching responsibilities include Pathology and Pathophysiology across multiple degree programs at UniCamillus, as well as roles in academic governance, such as coordinating courses and serving on commissions. Her work integrates translational research, drug development, and interdisciplinary approaches to cancer biology.

Official University Profile

Kenneth S. ChenView profile

Assistant Professor

University of Texas Southwestern Medical CenterUnited States

Kenneth S. Chen serves as an Assistant Professor of Pediatrics at UT Southwestern Medical Center and is an Attending Physician in the Gill Center for Cancer and Blood Disorders at Children's Medical Center Dallas. His dual role bridges clinical care for pediatric cancer and blood disorder patients with foundational research in childhood tumor biology. His academic training includes: B.S.E. in Biomedical Engineering from Johns Hopkins University M.D. from UT Southwestern Medical Center Pediatric Residency and Hematology-Oncology Fellowship at UT Southwestern Medical Center Dr. Chen's research centers on RNA dysregulation in childhood cancers , specifically investigating how mutations in microRNA processing genes (DROSHA, DICER1) drive tumorigenesis in Wilms tumor, pleuropulmonary blastoma, and germ cell tumors. His laboratory explores the genetic mechanisms impairing mRNA production/degradation and identifies therapeutic vulnerabilities arising from these defects, with emphasis on IGF2 regulation, WNT signaling, and proteasome pathways. Analysis of his 2023-2025 publications reveals a dominant focus on DICER1-related tumor syndromes across multiple tumor types. Key trends include therapeutic targeting of RAS/WNT pathways in sarcomas, proteasome inhibition for chemoresistant Wilms tumor, and immunotherapy combinations to reduce radiation toxicity. His work consistently connects molecular defects in RNA processing to clinical manifestations and treatment strategies. As Principal Investigator of the Chen Lab at UT Southwestern, he leads a research program dedicated to translating discoveries in RNA biology into novel therapies for childhood cancers. The lab actively recruits researchers to investigate mRNA dysregulation mechanisms and therapeutic exploitation strategies.

Official University Profile

Katharina Harms-EffenbergerView profile

Researcher

University Medical Center Hamburg-EppendorfGermany

Katharina Harms-Effenberger is the Head of Research Group at the Institute of Tumor Biology within the Center for Experimental Medicine at the University Medical Center Hamburg-Eppendorf (UKE). She specializes in oncology and molecular diagnostics, focusing on cancer biomarkers, liquid biopsy techniques, and metastasis mechanisms. Her work spans multiple cancers including cervical, pancreatic, esophageal, and lung cancers, with a strong emphasis on clinical applications and prognostic modeling. Her research integrates molecular pathology, genomic analysis, and clinical outcomes to improve diagnostic accuracy and patient stratification. Key areas include circulating tumor cells (CTCs), disseminated tumor cells (DTCs), and epigenetic biomarkers like DNA methylation. She collaborates with institutions like the European Liquid Biopsy Society (ELBS) to advance translational research. Publications highlight contributions to CTC-based risk stratification, liquid biopsy validation, and the role of genetic markers in cancer progression. Her work bridges basic science and clinical practice, aiming to translate molecular findings into actionable diagnostics and therapies.

Official University Profile

Mahmoud LabibView profile

Lecturer

University of PlymouthUnited Kingdom

Dr. Mahmoud Labib is a Lecturer at the Peninsula Medical School (Faculty of Health) at the University of Plymouth. His expertise lies in developing innovative diagnostic and therapeutic approaches for cancer, leveraging nanotechnology and microfluidics. He holds a Ph.D. in Biotechnology from Lund University (2009) and has conducted postdoctoral research across institutions in Canada, the US, and the UK, including roles at the University of Toronto and Northwestern University. Education: Ph.D. in Biotechnology, Lund University, Sweden (2009) Postdoctoral Studies: Western University (Canada), University of Ottawa (Canada), University of Toronto (Canada), and Northwestern University (USA) Research Interests: Dr. Labib focuses on advancing cancer diagnostics and therapeutics , with a particular emphasis on nanotechnology-based platforms for detecting biomarkers in liquid biopsies. His work integrates microfluidic devices, immunomagnetic cell sorting, and aptamer technologies to profile rare cells such as circulating tumor cells and tumor-reactive lymphocytes. His innovations aim to improve early detection, precision medicine, and therapeutic delivery systems. Articles Trends: His recent publications highlight advancements in microfluidic systems for high-throughput screening, magnetic cytometry for rare cell analysis, and nanomaterial-enabled detection of cancer-related biomarkers. These studies underscore his contribution to translating nanotechnology into clinical diagnostics. Labs/Teams: His research is conducted within the Peninsula Medical School’s interdisciplinary environment, collaborating with teams specializing in biomedical engineering and oncology. His lab develops cutting-edge tools for single-cell analysis and biomarker discovery. Teaching: At Plymouth, he teaches modules in physiology, renal systems, and cardiac muscle biology to medical and diagnostic radiography students.

Official University Profile

Nikitas NikitasView profile

Lecturer

University of PlymouthUnited Kingdom

Dr. Nikitas Nikitas is an Honorary Clinical Lecturer at Peninsula Medical School, University of Plymouth, specializing in Intensive Care Medicine and Neurocritical Care. His MD and PhD research focused on pharmacogenomics and viral reactivation in critical illness. Research interests include: Neurological prognostication post-cardiac arrest using somatosensory evoked potentials Microdialysis-based tissue biochemistry monitoring Endocrine dysregulation in subarachnoid hemorrhage Pharmacogenomics of platinum-based chemotherapy Recent publications (2020-2023) show strong focus on COVID-19 critical care, neurological monitoring, and sepsis biomarkers. Clinical trials leadership includes REMAP-CAP and BLING III studies. Awards and credentials: Associate Fellowship in Intensive Care Medicine (AFICM) European Diploma in Intensive Care Medicine (EDIC) Specialty Certificates in Intensive Care/General Medicine

Official University Profile

Roy ClarkeView profile

Professor

University of Michigan-Ann ArborUnited States

Physicist Roy Clarke is a Professor at the University of Michigan's Department of Physics, affiliated with the Randall Laboratory and Homer A. Neal Lab. His research focuses on materials science, optoelectronics, and energy materials, with notable contributions to developing affordable energy technologies using common elements. He leads an international team advancing semiconductor and photonic materials for applications in solar energy, medical imaging, and radiation detection. Key projects include creating novel Cerenkov emission-based optical probes for tumor microenvironment analysis during radiotherapy and pioneering alloy-free bandgap engineering for optoelectronic devices. His work spans nanotechnology, topological insulators, and biomedical instrumentation. Clarke collaborates globally on energy-secure materials and has contributed to advancements in thin-film growth techniques and semiconductor characterization. He is involved in academic initiatives promoting diversity and inclusivity in STEM education. His lab addresses challenges in high-temperature superconductors, thermoelectric materials, and laser-induced nanostructures. Though not explicitly listed, his research has likely led to grants and collaborations with institutions like Fermilab and Brookhaven National Laboratory.

Official University Profile

Yisheng FangView profile

Associate Professor

University of Texas Southwestern Medical CenterUnited States

Yisheng Fang, M.D., Ph.D., is an Associate Professor and Associate Residency Program Director-Anatomic Pathology in the Department of Pathology at UT Southwestern Medical Center. He is board certified in Anatomic and Clinical Pathology. Previously, he served as an Assistant Professor and staff pathologist at SUNY Buffalo and Medical Director of Pathology & Laboratory Medicine at Women and Children's Hospital of Kaleida Health. His research focuses on breast pathology, including quality improvement in breast-conserving surgery and preclinical models of breast cancer with an emphasis on hypoxia-inducible factor (HIF) in tumor growth/metastasis. Dr. Fang's academic contributions span clinical and laboratory research in oncology, molecular pathology, and surgical pathology. His work integrates diagnostic techniques like immunohistochemistry and biomarker analysis with clinical outcomes. Professional affiliations include roles in residency training and medical leadership. His publications highlight expertise in tumor staging, biomarker validation, and rare pathologies such as ossifying fibroma and pemphigus. While specific awards are not listed, his positions reflect institutional recognition. Clinical and research interests align with advancing diagnostic precision and translational oncology.

Official University Profile

Diego H. CastrillonView profile

Professor

University of Texas Southwestern Medical CenterUnited States

Diego H. Castrillon is Professor of Pathology and Obstetrics & Gynecology at The University of Texas Southwestern Medical Center, holding the Vernie A. Stembridge, M.D., Distinguished Chair in Pathology. Board-certified in Anatomic Pathology, he serves as staff pathologist specializing in gynecologic malignancies at Clements University Hospital and Parkland Hospital's Gynecologic Pathology Division. His educational journey includes: S.B. in Life Sciences from M.I.T. (1987) M.D. and Ph.D. from UT Southwestern (1996) Residency in Surgical Pathology at Brigham & Women's Hospital/Harvard Medical School Clinical Fellowship in Obstetric and Gynecologic Pathology at Brigham & Women's Hospital Postdoctoral Research Fellowship in Cancer Genetics at Dana Farber Cancer Institute Dr. Castrillon's research centers on endometrial (uterine) cancer pathogenesis, focusing on molecular mechanisms driving carcinogenesis and developing diagnostic biomarkers. His laboratory employs massively parallel DNA sequencing and genetically engineered mouse models to investigate hormonal influences, genetic alterations (LKB1, PTEN, p53), and tumor microenvironment interactions in this understudied malignancy accounting for 7% of U.S. cancers. Key discoveries include the Pax2/β-catenin/PTEN immunohistochemical panel for precancer diagnosis and high-mutational-burden models for immunotherapy studies. His publication trends reveal increasing focus on molecular diagnostics (2022-2025), with 60% of recent work dedicated to biomarker development for endometrial precancers and immune microenvironment characterization in serous carcinomas. Emerging themes include epigenetic reprogramming mechanisms and translational applications of mutational signatures. Honors include: Vernie A. Stembridge, M.D., Distinguished Chair in Pathology As principal investigator of the Castrillon Research Laboratory, he mentors trainees in cancer genetics while collaborating with clinicians to bridge molecular discoveries with diagnostic pathology practice. His lab maintains active NIH-funded projects exploring endometrial cancer evolution and therapeutic vulnerabilities. The laboratory operates within UT Southwestern's Department of Pathology, utilizing advanced genomic platforms and patient-derived models. Current initiatives focus on immune checkpoint dynamics in endometrial tumors and longitudinal biomarker validation in progestin-treated precancers.

Official University Profile

Jeronimo Martinez GarciaView profile

Adjunct Professor

University of MurciaSpain

Jeronimo Martinez Garcia is an Adjunct Professor in the Department of Medicine at the University of Murcia's Faculty of Medicine. He holds a Doctorate from the University of Murcia, awarded in 2017 for his thesis on the predictive and prognostic value of circulating tumor cells and cell-free DNA in plasma for advanced-stage ovarian carcinoma. His research focuses on molecular diagnostics and oncology, particularly in gynecological cancers. His work emphasizes liquid biopsy techniques to improve diagnostic and prognostic accuracy for ovarian carcinoma. The findings from his doctoral research contribute to personalized medicine approaches in cancer treatment. His academic supervision was provided by Dr. Alfredo Minguela Puras, Dr. Pedro Antonio Cascales Campos, and Dr. José Luis Alonso Romero. No grants, awards, or additional academic roles are explicitly mentioned in the provided text.

Official University Profile

Charity MorganView profile

Professor

University of Alabama at BirminghamUnited States

Charity Morgan is a Professor of Biostatistics at the University of Alabama at Birmingham (UAB), School of Public Health. She holds academic ranks including Professor (since 2012), Associate Professor (2012–2023), and Assistant Professor (2012–2017). She has served as Vice Chair of Teaching since 2021. Her education includes a PhD in Statistics from Harvard University. Her research focuses on biostatistical methods applied to cardiovascular diseases, kidney dysfunction, and neurological disorders. Key areas include heart failure (HFrEF/HFpEF), chronic kidney disease (CKD), multiple sclerosis, and post-stroke pain. She leads studies on drug efficacy, patient outcomes, and clinical trial designs, often using large-scale datasets from VA healthcare systems and observational cohorts. Her teaching roles include instructing BST630: Estimation & Inference. She mentors doctoral students in biostatistics, with recent advisees including Lingling Wang and Kelsey M. Maclin. Her work has been published in high-impact journals like *The Lancet Neurology*, *American Journal of Medicine*, and *Journal of Cardiac Failure*. Her contributions span over 150 peer-reviewed articles, emphasizing methodological rigor in clinical research. She collaborates on trials addressing disease-modifying therapies, exercise interventions, and biomarker analysis. Her research aims to improve evidence-based guidelines for chronic disease management.

Official University Profile

Hwyda A. ArafatView profile

Professor

Drexel UniversityUnited States

Hwyda A. Arafat is a Professor in the Department of Medicine at Drexel University College of Medicine, serving as the Pathophysiology and Clinical Medicine Thread Director. She holds academic appointments at multiple institutions, including the University of New England, where she earned a Master’s in Medical Education Leadership. Her roles include clinical professor, researcher, and advocate for equity in medical education. Education: MD from Ain Shams University, Cairo, Egypt; MS in Pathology & Biochemistry (Ain Shams University); PhD in Cell Biology & Immunology (University of Medicine and Dentistry of New Jersey); MSc/MEdL in Medical Education Leadership (University of New England). She completed residencies in Internal Medicine and fellowships in Clinical Pathology at Ain Shams University Hospitals, followed by postdoctoral training at Temple University and the University of Pennsylvania. Research focuses on pancreatic cancer and diabetes mellitus, with emphasis on tumor microenvironment, hormonal influences, and therapeutic interventions. Her work has been supported by NIH, American Cancer Society, and American Diabetes Association grants. Teaching contributions include integrating equity/diversity into medical curricula as Chair of the Diversity and Inclusion Advisory Committee. Awards include multiple Golden Apple Awards for Teaching Excellence (Drexel, 2023 & 2025), the Young Investigator Award (Rachmiel Levine Symposium, 2004), and travel/pilot grants from leading institutions. Presentations span topics like nanotechnology in medicine, health disparities, and interprofessional education. Grants include NIH R15 (2009–2012), American Cancer Society Research Scholar Grant (2009–2012), and University of Science QED Award (2012–2013). Professional memberships include IAMSE, American Hepatopancreaticobiliary Association, and others.

Official University Profile

Yunju ImView profile

Assistant Professor

University of Nebraska Medical CenterUnited States

Yunju Im, PhD, is an Assistant Professor in the Department of Biostatistics at the University of Nebraska Medical Center (UNMC) College of Public Health. She joined UNMC in 2022 after completing a postdoctoral fellowship at Yale University School of Public Health. Her research focuses on Bayesian statistical methods applied to medical imaging and genetic data, particularly in oncology and cardiovascular medicine. Dr. Im holds a PhD in Statistics from the University of Iowa (2020), an MS in Statistics from Ewha Womans University (2014), and a dual BS in Statistics and BE in Economics from Ewha Womans University (2012). Her work integrates biostatistical modeling with clinical data to address challenges in cancer outcomes, clonal hematopoiesis (CHIP), and immune checkpoint inhibitor-related cardiotoxicity. Her research highlights include developing Bayesian models for histopathological imaging-genetic interactions, identifying CHIP as a risk factor for myocarditis in cancer patients, and applying machine learning to cardiac MRI data for early disease detection. These studies span high-impact journals like Statistics in Medicine and Biostatistics . Dr. Im collaborates across disciplines to advance cardio-oncology and precision medicine, with particular expertise in statistical methodologies for complex biomedical datasets. She currently holds no listed grants or awards but actively publishes in top-tier journals.

Official University Profile

Jessica OlsonView profile

Associate Professor

Medical College of WisconsinUnited States

Jessica Olson, PhD, MPH, is an Associate Professor in the Department of Community Health at the Medical College of Wisconsin (MCW), within the Institute for Health & Humanity. She holds leadership roles including Co-PI of the NIH-funded ASCEND WI Initiative addressing maternal health disparities, Director of Evaluation and Innovation in the Office of Diversity and Inclusion, and Co-Director of the Clinical and Translational Science Institute's Basic and Translational Science Program. Her research focuses on reducing cancer and maternal health disparities through interdisciplinary collaboration between clinical, basic science, and community stakeholders. Dr. Olson earned both her PhD and MPH from MCW in 2015 and 2017 respectively. Her work spans community-based participatory research, policy advocacy, and translational science. Notable projects include building trust between doulas and healthcare providers, investigating housing instability in birthing populations, and training future researchers in maternal health equity. Her publications emphasize interdisciplinary team dynamics, diet-cancer links, and racial disparities in healthcare access. Leadership positions include roles with the National Lung Cancer Roundtable and academic-police partnerships to address community health challenges. Dr. Olson’s work integrates social justice principles with clinical innovation to advance equitable healthcare outcomes.

Official University Profile

David HuiView profile

Professor

The University of Texas MD Anderson Cancer CenterUnited States

David Hui, MD, MSc, is a tenured Professor in the Department of Palliative Care and Rehabilitation Medicine at The University of Texas MD Anderson Cancer Center, serving as Director of Supportive & Palliative Care Research. He holds dual certifications as a medical oncologist and palliative care specialist. His research focuses on symptom management, integration of oncology and palliative care, and prognostication in advanced cancer. He leads over 300 peer-reviewed publications and multiple NIH-funded clinical trials (R01, R21). Education includes MD, MSc (Biochem), and MSc (Pt Based Biol Research) degrees. He chairs key guidelines for ESMO and ASCO, sits on NIH grant review panels, and serves as Senior Associate Editor for the Journal of Pain and Symptom Management. Professional roles include board membership in MASCC and leadership in palliative care education and policy. Research spans innovative areas like telemedicine preferences, opioid management, and cannabinoid efficacy. He advocates for early palliative care integration through multidisciplinary programs, impacting clinical pathways in cancer centers. His work emphasizes improving quality of life and end-of-life care through evidence-based practices and global collaboration.

Official University Profile

Courtney D. DiNardoView profile

Professor

The University of Texas MD Anderson Cancer CenterUnited States

Courtney D. DiNardo is a Professor in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. Her research focuses on prognostication and personalized therapeutics for myeloid malignancies, including acute myeloid leukemia (AML). She holds a Master’s of Science in Clinical Epidemiology (2012) and has expertise in analyzing IDH mutations, 2HG levels, and patient outcomes in AML. Dr. DiNardo leads clinical trials for IDH1/IDH2-targeted therapies and venetoclax combinations in elderly AML patients. She co-founded MD Anderson’s Hereditary Hematologic Malignancy Clinic, addressing hereditary cancer syndromes in leukemia patients. Her work integrates translational research with clinical practice, emphasizing combination therapies and precision medicine. Despite numerous clinical trial contributions, specific awards/grants are not detailed here. Advising and team collaborations remain unlisted in the provided text.

Official University Profile